

**LOUISVILLE APL DIAGNOSTICS, INC.**  
**2622 NASA Pkwy Ste G2, Seabrook TX 77586 USA**  
**LAPL ELISA™ aβ<sub>2</sub>GPI IgM HRP Kit**




<b>REF</b>	<b>LAPL-K-HRP-aβ<sub>2</sub>GPI-1M</b>
------------	--

**An Enzyme Immunoassay**  
**For the Detection of IgM Anti-β<sub>2</sub> Glycoprotein I Antibodies**

<b>IVD</b>	<b>For <i>In Vitro</i> Diagnostic Use</b>
------------	---

**Technical Assistance**  
**Tel: 770-455-7129**  
**Fax: 770-455-6499**  
**Customer Support: 800-624-3192**  
 USA & Canada only  
**Email: [support@louisvilleapl.com](mailto:support@louisvilleapl.com)**  
**Suggestions: [feedback@louisvilleapl.com](mailto:feedback@louisvilleapl.com)**  
**Website: [www.louisvilleapl.com](http://www.louisvilleapl.com)**



**Corgenix, Inc.**  
 11575 Main Street, Suite 400  
 Broomfield, Colorado 80020, USA



<b>EC REP</b>
---------------

MT Promedt Consulting GmbH  
 Altenhofstrasse 80  
 D-66386 St. Ingbert/Germany

**EN**

**INSTRUCTIONS BOOKLET**  
**LAPL ELISA™ aβ<sub>2</sub>GPI IgA HRP Kit**

<b>TABLE OF CONTENTS</b>	<b>Page</b>
1 – Intended Use .....	3
2 – Explanation of the Test .....	3
3 – Principles of the Procedure .....	4
4 – Components .....	4
Warnings and Precautions .....	4
Storage and Handling .....	5
Specimen Collection and Handling .....	5
5 – Test Procedure .....	6
A. Material provided .....	6
B. Material required but not provided .....	6
C. Procedural Notes .....	6
D. Reagent Preparation .....	7
E. Assay procedure .....	8
6 – CALCULATION OF RESULTS .....	9
7 – QUALITY CONTROL .....	9
8 – NORMAL RANGE .....	10
9 – PERFORMANCE CHARACTERISTICS .....	10
Clinical Specificity .....	10
Normal Samples .....	10
Clinical Sensitivity .....	11
Systemic Lupus Erythematosus .....	11
SLE Controls .....	11
Primary Antiphospholipid Syndrome .....	11
Technical Performance Comparison .....	12
Precision .....	12
10 – LIMITATIONS OF THE TEST .....	12
Warranty .....	13
11 – REFERENCES .....	14

## 1 – INTENDED USE

The *LAPL ELISA™ aβ<sub>2</sub>GPI IgM HRP Kit* is an enzyme-linked immunosorbent assay (ELISA) for the semi-quantitative determination of IgM anti-Beta2 Glycoprotein I (β<sub>2</sub>GPI) antibodies in human serum or citrated plasma (3.2% sodium citrate).

The *LAPL ELISA™ aβ<sub>2</sub>GPI IgM HRP Kit* is intended for the detection and semi-quantitation of IgM anti-β<sub>2</sub>GPI antibodies in individuals with systemic lupus erythematosus (SLE) and lupus-like disorders (anti-phospholipid syndrome).

## 2 – EXPLANATION OF THE TEST

Anti-phospholipid antibodies are a heterogeneous group of immunoglobulins that bind to several anionic phospholipids, including cardiolipin and phosphatidylserine.<sup>1,2</sup> High serum levels of anti-phospholipid antibodies are frequently detected in patients with autoimmune (e.g., SLE) and non-autoimmune diseases, as well as in apparently healthy individuals.<sup>3,4</sup> These antibodies have been associated with an increased risk for recurrent arterial and venous thrombotic events, thrombocytopenia, and fetal loss. These manifestations are the main features of the anti-phospholipid syndrome (APS).<sup>5,6</sup> Most autoimmune anti-phospholipid antibodies require a serum cofactor (β<sub>2</sub>GPI) for optimal binding.<sup>7-10</sup> It has been shown that many anti-phospholipid antibodies may react to a neoepitope formed on the β<sub>2</sub>GPI molecule by the interaction between the phospholipid and β<sub>2</sub>GPI.<sup>11,12</sup> Most assays for anti-phospholipid antibodies contain bovine serum as the source of cofactor. More recently, it has been shown that the binding of β<sub>2</sub>GPI to the microwell surface may produce a neoepitope similar to that when combined with a phospholipid and the results with this system showed a good correlation with the anti-phospholipid syndrome.<sup>13-16</sup> The serologic detection of anti-β<sub>2</sub>GPI antibodies provides enhanced clinical sensitivity for thrombosis. The *LAPL ELISA™ aβ<sub>2</sub>GPI IgM HRP Kit* uses the well known ELISA format to detect anti-β<sub>2</sub>GPI antibodies in human serum.

Patients with positive reactions to both anti-phospholipid and anti-β<sub>2</sub>GPI assays were more likely to have clinical complications than those positive for only one. Higher prevalence and mean serum levels of IgM anti-β<sub>2</sub>GPI antibodies have been reported in autoimmune patients. In addition, anti-β<sub>2</sub>GPI antibodies in SLE patients correlated with clinical manifestations of anti-phospholipid syndrome.<sup>17</sup>

## 3 – PRINCIPLES OF THE PROCEDURE

The *LAPL ELISA™ aβ<sub>2</sub>GPI IgM HRP Kit* is performed as an indirect ELISA. Diluted serum or plasma samples, calibrator sera, and controls are incubated in microwells coated with purified human β<sub>2</sub>GPI. Incubation allows the anti-β<sub>2</sub>GPI antibodies present in the samples to react with the immobilized antigen. After the removal of unbound serum or plasma proteins by washing, antibodies specific for human IgM, labeled with horseradish peroxidase (HRP), are added forming complexes with the β<sub>2</sub>GPI bound antibodies. Following another washing step, the bound enzyme-antibody conjugate is assayed by the addition of a single solution containing tetramethylbenzidine (TMB) and hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>) as the chromogenic substrate. Color develops in the wells at an intensity proportional to the serum concentration of anti-β<sub>2</sub>GPI antibodies.

Results are obtained by reading the O.D. (optical density or absorbance) of each well in a spectrophotometer. Calibrator sera are provided, with the IgM anti-β<sub>2</sub>GPI antibody concentrations expressed in M units. For multipoint calibration, perform a linear regression analysis with calibrator values against calibrator O.D.s. Controls and patient results are determined from the calibration curve. These units are traceable to available reference preparations.

## 4 – COMPONENTS

Store at 2 - 8°C. Do Not Freeze.

Each *LAPL ELISA™ aβ<sub>2</sub>GPI IgM HRP Kit* contains the following reagents

(volumes may vary depending on the kit size and configuration):

- 12 x 8 stabilized β<sub>2</sub>GPI (from human serum) coated microwells with frame
- 60 mL Sample Diluent IV (blue-green solution)
- 3 vials (0.250 mL) IgM β<sub>2</sub>GPI Calibrator Serum\* (1-high, 2-moderate, 3-low) (human); see vial label for antibody concentration in M units.
- 0.250 mL IgM β<sub>2</sub>GPI Positive Control Serum\* (human); see vial label for expected M unit range
- 0.250 mL Normal Control Serum\* (human); see vial label for expected M unit range
- 15 mL anti-human IgM (goat) HRP-Conjugated Antibody Solution (blue solution)
- 15 mL One Component Substrate Solution (TMB and H<sub>2</sub>O<sub>2</sub>); ready to use
- 15 mL Stopping Solution (0.36 N sulfuric acid)
- 2 bottles (30 mL) Wash Concentrate (33X PBS/Tween)

\*CAUTION: Contains sodium azide.

## WARNINGS AND PRECAUTIONS

1. For *in vitro* use only.
2. Human source material used to prepare the calibrators and controls included in this kit has been tested and shown to be negative to HBsAg, HCV, and HIV 1 & 2 by

FDA required tests. However, all human blood derivatives, including patient samples, should be handled as potentially infectious material

3. Do not pipette by mouth.
4. Do not smoke, eat, or drink in areas where specimens or kit reagents are handled.
5. Wear disposable gloves while handling kit reagents and wash hands thoroughly afterwards.
6. Certain components of this product contain sodium azide as a preservative. Sodium azide has been reported to form lead and copper azides when left in contact with these metals. These metal azides are explosive. Any solutions containing azide must be thoroughly flushed with copious amounts of water to prevent the build-up of explosive metal azides in the plumbing system
7. One Component Substrate Solution can cause irritation to the eyes and skin. Use gloves when handling substrate and wash thoroughly after handling. Keep reagent away from ignition sources. Avoid contact with oxidizing agents.
8. Certain components are labeled with the following:  
Irritating to eyes (R 36). Avoid contact with skin (S 24). Avoid contact with eyes (S 25). In case of contact with eyes, rinse immediately with plenty of water and seek medical advice (S 26). If swallowed, seek medical advice immediately and show this container or label (S 46).

## STORAGE AND HANDLING

1. Store all reagents at 2-8°C when received. Avoid freezing reagents.
2. All reagents must be brought to room temperature (18 - 30°C) for 30 minutes prior to use.
3. Avoid direct sunlight.

## SPECIMEN COLLECTION AND HANDLING

No Serum or citrated plasma (3.2% sodium citrate) should be used as the sample matrix. Blood should be collected by venipuncture and the serum separated from the cells by centrifugation after clot formation. If not tested immediately, the specimens should be stored at 2 to 8°C. If specimens are to be stored for more than 72 hours, they should be frozen at -20°C or below. Avoid repeated freezing and thawing. Do not use hemolyzed, icteric, or lipemic serum or plasma as these conditions may cause aberrant results. Specimens containing visible particulate matter should be clarified by centrifugation before testing.

If citrated plasma is to be used, blood should be collected by venipuncture and the plasma separated from the cells immediately by centrifugation at 1500g for 10 minutes. The supernatant must be carefully removed after centrifugation to avoid contamination with platelets. Repeating the centrifugation and separation steps may be advisable to minimize platelet contamination. Lysed or aged platelets can lead to aberrant results. If not tested immediately, plasma samples should be stored as described for serum.

## 5 – TEST PROCEDURE

### A. Material provided

LAPL ELISA™  $\alpha\beta_2GPI$  IgM HRP Kit, see “Reagents” section for a complete list

### B. Material required but not provided

- Reagent grade water to prepare PBS wash solution (2L)
- Graduated cylinders
- Precision pipettors capable of delivering between 10  $\mu$ L and 1000  $\mu$ L, with appropriate tips
- Miscellaneous glassware appropriate for handling small volumes
- Flasks or bottles, 1 liter
- Wash bottles, preferably with the tip partially cut back to provide a wide stream, or an automated or semi-automated washing system
- Disposable gloves
- Plate-reading spectrophotometer capable of reading absorbance at 450 nm (650 nm reference if dual beam)
- Multichannel pipettors capable of delivering to 8 wells simultaneously
- Microdilution tubes and a 96-well microdilution tube holder for sample dilutions and rapid delivery to microwell plate Precision micropipettes with disposable plastic tips which deliver 10  $\mu$ L, 100  $\mu$ L, and 1 ml ( $\pm$ 2%)

### C. Procedural Notes

1. Bring serum or plasma samples and kit reagents to room temperature and mix well before using; avoid foaming. Return all unused samples and reagents to refrigerated storage as soon as possible.
2. All dilutions of calibrators, controls, and test sera or plasma must be made just prior to use in the assay.
3. A single water blank well can be included in each plate with each run. No sample or kit reagents are to be added to this well. Instead, add 200  $\mu$ L of reagent grade water to the well immediately prior to reading the plate in the spectrophotometer. The plate reader should be programmed to “zero” or “blank” against an air or a water well.
4. Good washing technique is critical for optimal performance of the assay. Adequate washing is best accomplished by directing a forceful stream of wash solution into the bottom of the microwells from a plastic squeeze bottle with a wide tip. Wash solution in the water blank well will not interfere with the procedure. An automated plate washing system can also be used.
5. **IMPORTANT:** Failure to adequately remove residual wash solution can cause inconsistent color development of the Substrate Solution.

6. Use a multichannel pipettor capable of delivering to 8 wells simultaneously when possible. This speeds the process and provides more uniform incubation and reaction times for all wells.
7. Carefully controlled timing of all steps is critical. All calibrators, controls, and samples must be added within a five minute period. Batch size of samples should not be larger than the amount that can be added within this time period.
8. For all incubations, the start of the incubation period begins with the completion of reagent or sample addition. Incubation periods of 30 minutes are recommended, however incubation periods of up to 40 minutes may be used with this format.
9. Addition of all samples and reagents should be performed at the same rate and in the same sequence.
10. Incubation temperatures above or below normal room temperature (18 to 26°C) may contribute to inaccurate results.
11. Avoid microbial and cross-contamination of reagents when opening and removing aliquots from the primary vials.
12. Do not use kit components beyond expiration date.
13. Do not use kit components from different kit lot numbers.

#### **D. Reagent Preparation**

##### **Wash Solution (PBS/Tween):**


Measure 30 mL of Wash Concentrate and dilute to 1 liter with reagent grade water. The pH of the final solution should be  $7.35 \pm 0.1$ . Store unused wash solution in the refrigerator at 2-8°C. Discard if the solution shows signs of microbial or cross-contamination.

#### **E. Assay procedure**

1. The assay is performed using a four-point calibration curve. (Calibrators 1, 2, and 3 plus sample diluents/reagent blank as Calibrator 4 equal to 0 A units.) A reagent blank control (Calibrator 4) must be run with each assay in which Sample Diluent without serum is added to the well. This well is then treated the same as sample wells in subsequent assay steps.
2. Remove any microwell strips that will not be used from the frame and store them in the bag provided.
3. Prepare a 1:50 dilution of the calibrators, controls, and patient samples in sample diluent (blue-green solution); e.g., 10 µL of sample added to 490 µL of Sample Diluent equals a 1:50 sample dilution.
4. Add 100 µL of diluted calibrators (including the reagent blank/Calibrator 4), controls, and patient samples to the appropriate microwells.
5. Incubate 30 minutes at room temperature. After the incubation is complete, carefully invert the microwells and empty the sample fluid. Do not allow samples to contaminate other microwells.
6. Wash 4 times with wash solution. Each well should be filled with wash solution per wash. Invert microwells between each wash to empty fluid. Use a snapping motion of the wrist to shake the liquid from the wells. To retain microwell modules during washing, the frame must be squeezed at the top and bottom of the longest sides. Blot on absorbent paper to remove residual wash fluid. Do not allow wells to dry out between steps.
7. Add 100 µL anti-human IgM HRP-Conjugated Antibody Solution (red) to the wells.
8. Incubate for 30 minutes at room temperature. After the incubation is complete, carefully invert the microwells and empty the conjugate solution.
9. Wash 4 times with wash solution, as in step 6. Use a snapping motion to drain the liquid, and blot on absorbent towels after the final wash. Do not allow the wells to dry out.
10. Add 100 µL One Component Substrate to each well and incubate for 30 minutes at room temperature. Add substrate to the wells at a steady rate. Blue color will develop in wells with positive samples.
11. Add 100 µL Stopping Solution (0.36 N sulfuric acid) to each well to stop the enzyme reaction. Be sure to add the acid to the wells in the same order and at the same rate as the Substrate was added. Blue Substrate will turn yellow and colorless solution will remain colorless. Blank or zero the plate reader against an air or a water blank well. Read the O.D. of each well at 450 nm (and 650 nm reference if dual beam). The O.D. values should be measured within 5 minutes of the addition of the Stopping Solution.

## 6 – CALCULATION OF RESULTS

1. Calculate the mean O.D. values if duplicates of the calibrators, controls and patient samples were performed.
2. Perform linear regression or quadratic/2nd order polynomial regression analysis with the four calibrator values against the mean O.D.s for each calibrator (see vial labels for M units; Calibrator 4 [sample diluent] is equal to 0 M units).
3. The calibrator curve can be plotted either automatically using a validated software program or manually with graph paper. It is recommended to use a zero intercept when generating the regression line to avoid negative values. If this option is not available, any negative values should be reported as zero units. When generating the curve manually, draw a best fit line through the plotted points using a zero intercept.
4. Determine the control and patient sample values from the calibrator curve.
5. Example of a multi-point curve calibration.



Using the example calibration curve provided, a specimen O.D. of 0.860 at 450 nm would correspond to a calculated value of 60 units. The calibration curve provided is an example only and should not be used to calculate patient results. A new calibration curve should be performed with every test run

## 7 – QUALITY CONTROL

1. The O.D. value of Calibrator 2 should be at least 0.600 to assure that the kit is functioning properly. Calibrator 2 O.D. readings of less than 0.600 may indicate that the kit is no longer suitable for use.

2. The O.D. of Calibrator 4 or reagent blank should be less than 0.050 when the spectrophotometer has been blanked against air or a water well. Readings greater than 0.050 may indicate possible reagent contamination or inadequate plate washing.
3. The anti- $\beta_2$ GPI values obtained for the control sera should be within the ranges indicated on the vial labels. Occasional small deviations outside these ranges are acceptable.
4. O.D. values for duplicates of the controls or patient samples should be within 20% of the mean O.D. value for samples with absorbance readings greater than 0.200.
5. Each laboratory should periodically determine its own normal cut-off values for the appropriate population of patients.
6. Samples with anti- $\beta_2$ GPI values greater than 200 M units may be reported as “greater than 200 M units.”
7. Assure that all quality control parameters have been met before reporting test results.

## 8 – NORMAL RANGE

Serum samples from 120 healthy blood donors were tested for IgM anti- $\beta_2$ GPI antibodies. The following normal range was established:

- Less than 20 M units

## 9 – PERFORMANCE CHARACTERISTICS

### Clinical Specificity

#### *Normal Samples*

Serum samples from 120 healthy blood donors were assayed for the presence of IgM anti- $\beta_2$ GPI antibodies. Using the establish cutoff value of 20 M units, this normal population demonstrated 93% specificity (mean value = 7.7 M units). Serum samples from 41 infectious disease (syphilis), 42 progressive systemic sclerosis (PSS), and 42 rheumatoid arthritis (RA) patients were assayed for the presence of IgM anti- $\beta_2$ GPI antibodies. These patient groups demonstrated similar results compared to the healthy blood donor population (mean values = 9.7, 10.1, and 11.1 M units respectively). Results of these groups along with the healthy blood donors are summarized in the table below.

	Healthy	Infectious (syphilis)	PSS	RA
# of Samples (n)	120	41	42	42
Mean (M units)	7.7	9.7	10.1	11.1
Standard Deviation	9.5	17.9	15.1	16.0
% Negative	92.5%	95.0%	92.9%	88.1%

Clinical Sensitivity

**Systemic Lupus Erythematosus (SLE):**

Serum samples from 40 unselected (consecutive) patients with SLE were tested with this kit. Eight of the samples (sensitivity of 20%) were positive for IgM anti-β<sub>2</sub>GPI antibodies (mean value = 14 M units).

Serum samples from 12 selected female patients with SLE who had a clinical history of thrombosis, thrombocytopenia or recurrent fetal loss were evaluated for IgM anti-β<sub>2</sub>GPI antibodies. Five of the samples (sensitivity of 42%) were positive in this population (mean value = 24 M units).

**SLE Controls:**

Serum samples from five selected female patients with SLE who had history of thrombocytopenia (no thrombosis) were tested for IgM anti-β<sub>2</sub>GPI antibodies. None tested positive, and the resulting mean value was 6 M units for this group.

Serum samples from nine selected female patients with SLE who were known not to have had thrombotic episodes, nor any other feature of the anti-phospholipid syndrome, were tested in the assay. One sample (11%) was weak positive for IgM anti-β<sub>2</sub>GPI antibodies, with a mean value of 9 M units for this group.

**Primary Anti-phospholipid Syndrome (APS):**

Serum samples from nine patients with the diagnosis of primary anti-phospholipid syndrome (APS) were tested on the *LAPL ELISA™ aβ<sub>2</sub>GPI IgM HRP* (Lot GW-001). Three of the nine samples resulted positive (33.3% sensitivity) with a mean value of 32.7 M units. A summary of sensitivity testing is presented below:

	Unselected SLE	Selected SLE		Primary APS
		No Thrombosis	Thrombosis	
# of Samples (n)	40	14	12	9
Mean (M units)	13.9	8.0	24.4	32.7
Standard Deviation	18.1	10.3	24.8	37.3
% Positive	20.0%	7.1%	41.7%	33.3%

Technical Performance Comparison

Two disease populations (unselected SLE and primary APS) were tested on the *LAPL ELISA™ aβ<sub>2</sub>GPI IgM HRP Kit* and a predicate device to study the correlation between positive and negative results. The results are summarized in the table presented below

		<i>LAPL ELISA™ aβ<sub>2</sub>GPI IgM HRP Kit</i>	
		Negative	Positive
Predicate Device IgM anti-β <sub>2</sub> GPI	Negative	35	4
	Positive	3	7

Relative Sensitivity	70%
Relative Specificity	90%
Agreement	86%

Precision

Three samples with known M unit values (one low, one moderate, and one high) were assayed in 23 replicates on three different occasions. The mean intra-assay and inter-assay coefficients of variation (%CVs) are presented in the table below. The reported intra-assay coefficient of variation is the mean of the three separate intra-assay CVs. Inter-assay CV is the coefficient of variation obtained from three plates from one lot.

	Value Range	Intra-assay Mean %CV	Inter-assay Mean %CV
Low	13 - 16 M units	3.8%	6.1%
Moderate	44 - 56 M units	3.5%	4.5%
High	73 - 82 M units	2.4%	3.4%

**10 – LIMITATIONS OF THE TEST**

The anti-β<sub>2</sub>GPI antibody concentration values obtained from this assay are an aid to diagnosis only. Each physician must interpret these results in light of the patient’s history, physical findings, and other diagnostic procedures. If clinical findings suggest the presence of anti-phospholipid antibodies and the patient is negative for anti-β<sub>2</sub>GPI antibodies, some investigators recommend testing for anti-cardiolipin antibodies, anti-phosphatidylserine antibodies, and the lupus anticoagulant to confirm the negative result. A patient may be considered positive for anti-

phospholipid antibodies if one or all of the tests give positive results.

### **Warranty**

This product is warranted to perform as described in this package insert. The Manufacturer disclaims any implied warranty of merchantability or fitness for a particular use, and in no event shall The Manufacturer be liable for consequential damage.

## **11 – REFERENCES**

1. McNeil HP, Chesterman CN, Krilis SA. Immunology and clinical importance of antiphospholipid antibodies. *Adv Immunol* 1991; 49:193-280.
2. Harris EN. Annotation. Antiphospholipid antibodies. *Br J Haematol* 1990; 74:1-9.
3. Love PE, Santoro SA. Antiphospholipid antibodies: Anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Prevalence and clinical significance. *Ann Intern Med* 1990; 112:682-698.
4. Sammaritano LR, Gharavi AE, Lockshin MD. Antiphospholipid antibody syndrome: immunologic and clinical aspects. *Seminars in Arthritis and Rheumatism* 1990; 20:81-96.
5. Hughes GRV, Harris EN, Gharavi AE. The anticardiolipin syndrome (Editorial). *J Rheumatol* 1986; 13:486-489.
6. Hughes GRV. The antiphospholipid syndrome: ten years on. *Lancet* 1993; 342:341-344.
7. McNeil HP, Simpson RJ, Chesterman CN. Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation:  $\beta$ 2-Glycoprotein I (apolipoprotein H). *Proc Natl Acad Sci USA* 1991; 87:4120-4124.
8. Galli M, Comfurius P, Maassen C. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. *The Lancet* 1990; 335:1544-1547.
9. Matsuura E, Igarashi Y, Fujimoto M. Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease. *The Lancet* 1990; 336:177-178.
10. Roubey R. Immunology of the antiphospholipid antibody syndrome. *Arthritis & Rheumatism* 1996; 39:1444-1454.
11. Wagenknecht D, McIntyre J. Changes in  $\beta$ 2-Glycoprotein I antigenicity induced by phospholipid binding. *Thrombosis and Haemostasis* 1993; 64:361-365.
12. Pengo V, Biasiolo A, Grazia Fior M. Autoimmune antiphospholipid antibodies are directed against a cryptic epitope expressed when  $\beta$ 2-glycoprotein I is bound to a suitable surface. *Thrombosis and Haemostasis* 1995; 73:29-34.
13. Matsuura E, Igarashi Y, Tasuda T. Anticardiolipin antibodies recognize  $\beta$ 2-glycoprotein I structure altered by interacting with an oxygen modified solid phase surface. *J Exp Med* 1994; 179:457-462.
14. Keil L, Galazka H, El-Kakdi HS. Binding of  $\beta$ 2-glycoprotein I to activated polystyrene and its recognition by human IgG autoantibodies. *Biotechnol Appl Biochem* 1995; 22:305-313.

15. Amengual O, Atsui T, Khamasgta MA. Specificity of ELISA for antibody to beta 2-glycoprotein I in patients with antiphospholipid syndrome. *Br J Rheumatol* 1996; 35:1239-1243.
16. Tsutsumi A, Matsuura E, Ichikawa K. Antibodies to  $\beta$ 2-glycoprotein I and clinical manifestations in patients with systemic lupus erythematosus. *Arthritis & Rheumatism* 1996; 39:1466-1474.
17. Lopez L, Dier K, Lopez D, Merrill J, Fink C. Anti- $\beta$ 2-Glycoprotein I and Antiphosphatidylserine Antibodies Are Predictors of Arterial Thrombosis in Patients With Antiphospholipid Syndrome. *Am J Clin Pathol* 2004;121:142-149

Louisville APL Diagnostics, Inc.

*Revision #5 –March 31<sup>st</sup>, 2013*

REF	LAPL-K-HRP-a $\beta$ 2GPI-1M
-----	------------------------------